Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.34 |
| ▸ | RET | P07949 | 5/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17354480 | 0.93 | IGF1R (0.36) | IGF1RCHEK1ROCK2LIMK1 | |
| SCHEMBL14147 | 0.90 | KDR (0.38) | IGF1RP2RY1RETKDR | |
| SCHEMBL17354474 | 0.90 | IGF1R (0.40) | IGF1RP2RY1RETKDRKCNH2 | |
| SCHEMBL17354506 | 0.89 | IGF1R (0.38) | IGF1RCHEK1ROCK2LIMK1 | |
| SCHEMBL17486551 | 0.88 | IGF1R (0.35) | IGF1RCHEK1ACHE | |
| SCHEMBL17486571 | 0.88 | IGF1R (0.38) | IGF1RROCK2LIMK1 | |
| SCHEMBL17354162 | 0.87 | KDR (0.36) | KDRROCK2LIMK1 | |
| SCHEMBL17486554 | 0.87 | P2RY1 (0.35) | IGF1RP2RY1RETKDRKCNH2 | |
| SCHEMBL17486573 | 0.87 | IGF1R (0.35) | IGF1RCHEK1 | |
| SCHEMBL13768 | 0.85 | CA12 (0.34) | IGF1RRETKDRROCK2LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2016-02-04 | — | — | US | disclosed |
| US-9216979-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031828-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | IGF1R 4795/4885P2RY1 3578/4885RET 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.